Last reviewed · How we verify
NCT06788223: PTeye
Intraoperative Identification of Parathyroid Adenomas Using PTeye™ and FLUOBEAM® LX: a Prospective Cohort Study
trial testing Parathyroidectomy in Primary Hyperparathyroidism Due to Adenoma in 40 participants. Participants enrolled and being followed up; not accepting new ones.
31 January 2025
Quick facts
| Lead sponsor | Aristotle University Of Thessaloniki |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 November 2024 |
| Primary completion | 31 January 2025 |
| Estimated completion | 31 January 2025 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Parathyroidectomy
Conditions studied
- Primary Hyperparathyroidism Due to Adenoma — all drugs for Primary Hyperparathyroidism Due to Adenoma →
Sponsor
Aristotle University Of Thessaloniki
Who can join
Eligibility, any sex, with Primary Hyperparathyroidism Due to Adenoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to evaluate the efficacy of PTeyeTM device to confirm a parathyroid adenoma on a visually suspected tissue in comparison with the FLUOBEAM®LX device. The main questions it aims to answer is: Is the PTeyeTM device effective in identifying the presence of a parathyroid adenoma? Which autofluorecence device (PTeye or FLUOBEAM®LX) is more effective in confirming the presence of a parathyroid adenoma? Participants will undergo parathyroidectomy under general anesthesia. During the procedure visually suspected tissue for parathyroid adenoma will be evaluated with the PTeye or FLUOBEAM®LX device for the presence of an adenoma (minute 0). Tissue will be reevaluated on minutes 1, 3, and 5 and before excision.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Assessment of PTeye™ versus FLUOBEAM® LX for parathyroid adenomas: a pilot case-control study.
Papavramidis T, Chorti A, Bakkar S. · · 2025 · PMID 40730739 · DOI 10.1007/s13304-025-02334-7
Verify or expand the search:
- PubMed search for NCT06788223
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Parathyroidectomy
Trials testing the same drug.
- NCT06708871 — Thermal Ablation Versus Parathyroidectomy for Primary Hyperparathyroidism · not yet recruiting
- NCT07138820 — 18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased · NA · recruiting
- NCT04922892 — Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism · NA · recruiting
- NCT03011736 — Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism · NA · completed
Other Aristotle University Of Thessaloniki trials
Trials by the same sponsor.
- NCT07382479 — NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery · NA · not yet recruiting
- NCT07379905 — MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1) · NA · not yet recruiting
- NCT07335016 — The Role of Follicular Flushing at Oocyte Retrieval · NA · not yet recruiting
- NCT07297121 — Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece. · not yet recruiting
- NCT07210164 — Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06788223 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aristotle University Of Thessaloniki
- Last refreshed: 24 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06788223.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing